Study of Acamprosate in Autism
Completed · Phase 1 · Has a placebo group
Conditions studied: Autistic Disorder
In brief
Recent pharmacotherapy research in autism spectrum disorders (ASD) has successfully focused on treatment of co-occurring symptoms, including inattention, hyperactivity, and irritability that commonly occur in persons with ASD. Despite over two decades of significant pharmacotherapy research, to date no medication has been shown in controlled trials to enhance the core social deficits of ASD. Based upon findings describing the neurobiology of ASD combined with our preliminary results, we believe the novel drug acamprosate will show evidence of reducing social skills deficits associated with ASD.
Key facts
- Study ID
- NCT01813318
- Run by
- Children's Hospital Medical Center, Cincinnati
- People needed
- 36
- Starts
- 2013-07-02
- Expected to finish
- 2017-09-07
- Last updated by the study team
- 2021-02-03
Who can join
Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 5-17 year-old outpatients
- Diagnosis of ASD
- General good health (determined by exam, history, and laboratory work up)
- Use of up to two concomitant psychotropic drugs (stable dosing for >60 days) not impacting glutamate or gamma-aminobutyric acid A (GABA) neurotransmission is allowed
- Stable seizure disorder (no seizures in 6 months; on same anti-convulsant dose for >60 days)
- Clinical Global Impression Scale Severity score (CGI-S) of 4 (Moderately III)
- Score of 13 on the Social Withdrawal subscale of the Aberrant Behavior Checklist (ABC-SW) at screen and baseline
You may not qualify if…
- Potential subjects with a creatinine clearance < 50 mL/min or evidence of a previous trial of acamprosate will be excluded
Where it is running
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.